Pinnacle Associates’s Caribou Biosciences CRBU Stock Holding History

Pinnacle Associates’s Portfolio CRBU Stock Details CRBU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.7K	Hold	12,903	–	–	﹤0.01%	967
2026 Q1	$24.5K	Hold	12,903	–	–	﹤0.01%	954
2025 Q4	$20.5K	Hold	12,903	–	–	﹤0.01%	931
2025 Q3	$30.1K	Hold	12,903	–	–	﹤0.01%	862
2025 Q2	$16.3K	Hold	12,903	–	–	﹤0.01%	845
2025 Q1	$11.8K	Hold	12,903	–	–	﹤0.01%	823
2024 Q4	$20.5K	Hold	12,903	–	–	﹤0.01%	832
2024 Q3	$73.9K	Hold	12,903	–	–	﹤0.01%	786
2024 Q2	$21.2K	Hold	12,903	–	–	﹤0.01%	810
2024 Q1	$66.3K	Hold	12,903	–	–	﹤0.01%	821
2023 Q4	$73.9K	Hold	12,903	–	–	﹤0.01%	800
2023 Q3	$61.7K	Hold	12,903	–	–	﹤0.01%	795
2023 Q2	$54.8K	Hold	12,903	–	–	﹤0.01%	804
2023 Q1	$68.5K	Hold	12,903	–	–	﹤0.01%	756
2022 Q4	$81K	Hold	12,903	–	–	﹤0.01%	740
2022 Q3	$136K	Hold	12,903	–	–	﹤0.01%	711
2022 Q2	$70K	Buy	+12,903	New	+$98.6K	﹤0.01%	731

Other funds holding CRBU

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Pinnacle Associates's CRBU Position: Q2 2026 in Review

Pinnacle Associates held its Caribou Biosciences (CRBU) position steady in Q2 2026 at 12,903 shares worth $22.7K. The position accounts for ﹤0.01% of the portfolio, ranked #967.

Pinnacle Associates first reported a position in CRBU in Q2 2022 and has held it in 17 quarters since. The position peaked at $136K in Q3 2022. 137 funds tracked by Wall St. Rank hold CRBU as of Q2 2026.

Pinnacle Associates held 12,903 shares of Caribou Biosciences worth $22.7K as of Q2 2026.
Pinnacle Associates left its Caribou Biosciences share count unchanged in Q2 2026.
Caribou Biosciences made up ﹤0.01% of Pinnacle Associates's portfolio in Q2 2026, its #967 holding.
Pinnacle Associates first reported a position in Caribou Biosciences in Q2 2022 and has held it in 17 quarters since.
Pinnacle Associates's Caribou Biosciences position peaked at $136K in Q3 2022.
137 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2026.

Based on Pinnacle Associates's 13F filing for Q2 2026, filed 3 Aug 2026.